Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966467 · ClinicalTrials.gov registry record
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
A clinical trial of Neuromyelitis Optica Spectrum Disorder and NMOSD, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 122
- Enrollment target
- 20
- Study locations
NCT05966467 is a study of Neuromyelitis Optica Spectrum Disorder and NMOSD that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 122 participants, above the 46-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT05966467, a study of Neuromyelitis Optica Spectrum Disorder and NMOSD, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 122 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Beijing
- Clinical Trial Site - Guangzhou
- Clinical Trial Site - Henan
- Clinical Trial Site - Shanghai
- Clinical Trial Site - Sichuan
- Clinical Trial Site - Wuhan
- Clinical Trial Site - Dresden
- Clinical Trial Site - Essen
- Clinical Trial Site - München
District of Columbia
- Clinical Trial Site - Washington D.C.
Massachusetts
- Research Site - Boston
North Carolina
- Clinical Trial Site - Chapel Hill
Ohio
- Clinical Trial Site - Columbus
Texas
- Clinical Trial Site - Plano
Wisconsin
- Clinical Trial Site - Milwaukee
British Columbia
- Clinical Trial Site - Burnaby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2030-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966467
The ClinicalTrials.gov registry entry for NCT05966467 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (165% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neuromyelitis Optica Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT05966467 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05966467 about?
NCT05966467 is a clinical study titled "Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies". Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality ...
What is the current status of trial NCT05966467?
This trial is currently recruiting. The enrollment target is 122 participants. The study started on 2024-02-01. Estimated completion is 2030-03-01.
What conditions does trial NCT05966467 study?
This clinical trial studies the following conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ Nmosd.
Who is sponsoring clinical trial NCT05966467?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966467 being conducted?
This trial has 20 study locations across District of Columbia, Massachusetts, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
RECRUITING · Phase 3
-
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
RECRUITING
-
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
RECRUITING · Phase 2
-
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
RECRUITING · Phase 2
-
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
ACTIVE NOT RECRUITING · Phase 4
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Neuromyelitis Optica Spectrum Disorder
All registered trials for this condition
NMOSD
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.